Multimodal molecular imaging in drug discovery and development |
| |
Affiliation: | 1. The Maastricht MultiModal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands;2. Development Science, UCB Biopharma SRL, Chemin du Foriest, B1420 Braine-l’Alleud, Belgium;3. DMPK, UCB Celltech, Branch of UCB Pharma SA, 208 Bath Road, Slough SL1 3WE, UK |
| |
Abstract: | In addition to individual imaging techniques, the combination and integration of several imaging techniques, so-called multimodal imaging, can provide large amounts of anatomical, functional, and molecular information accelerating drug discovery and development processes. Imaging technologies aid in understanding the disease mechanism, finding new pharmacological targets, and assessment of new potential drug candidates and treatment response. Here, we describe how different imaging techniques can be used in different phases of drug discovery and development and highlight their strengths, related innovations, and future potential with a focus on the implementation of artificial intelligence (AI) and radiomics for imaging technologies. |
| |
Keywords: | Multimodal imaging Molecular imaging Artificial intelligence Radiomics Preclinical research |
本文献已被 ScienceDirect 等数据库收录! |
|